Novartis Rydapt wins EU approval for AML, other diseases Ruby Khatun Khatun22 Sep 2017 4:27 AM GMTZURICH: Swiss drugmaker Novartis on Wednesday won European Union approval for Rydapt to be used against a mutated form of acute myeloid leukemia (AML)...